Abstract
The recent release of new, non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field. Ongoing research portends the arrival of a wide range of cffDNA tests. However, it is not yet clear how these tests will be integrated into well-established prenatal testing strategies in the USA, as the timing of such testing and the degree to which new non-invasive tests will supplement or replace existing screening and diagnostic tools remain uncertain. We argue that there is an urgent need for policy-makers, regulators and professional societies to provide guidance on the most efficient and ethical manner for such tests to be introduced into clinical practice in the USA.
Original language | English (US) |
---|---|
Pages (from-to) | 3123-3131 |
Number of pages | 9 |
Journal | Human Reproduction |
Volume | 27 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2012 |
Keywords
- aneuploidy
- ethics
- prenatal diagnosis
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology